We combine medical expertise with human-centered design and development of digital health tools. We are supported by an Advisory Board of key opinion leaders in respiratory care, digital health and medical devices.
LiveLunger has created LungBeat®, a clinically validated medical app designed to support chronic respiratory patients in their daily asthma self-management. LungBeat utilizes a Bluetooth-connected spirometer connection, providing regular insights into your current lung capacity.
If you experience any complaints at home or notice changes in your symptoms, simply answer three questions, and LungBeat will guide you on which personalized action plan to follow.
LungBeat® developed by LiveLunger, is designed for asthma patients and their families. It provides peace of mind, knowing that you have a digital assistant to guide you on how you feel. Additionally, LungBeat offers a direct link to your care team.
LiveLunger’s LungBeat is developed for asthma patients and their family. It offers them a digital assistent closeby to consult in between face-to-face consultations in the hospital. Like this, healthcare professionals, can build on more continuous data streams and can have insights into how the patients are doing when they are at home, in between consultations.
Moreover, we are looking for clinical partnerships to extend LungBeat with features that can increase the power of telemonitoring in a meaningful clinical way.
Within your client base 3-5% experience severe asthma and receive biological therapies. These treatments are costly and necessitate strict adherence to medication plans. Clinical studies have demonstrated that LungBeat enhances the patients’ therapy adherence rates. Maintaining adherence to therapy not only improves daily outcomes and quality of life for patients but also contributes to cost savings for social security and health insurance funds.
Among your clients 3-5% suffer from severe asthma and receive biological therapies. These therapies are expensive and require a patient to be strictly compliant to medication plans. Clinical studies have shown that LungBeat improves the therapy adherence rate of patients. This can significantly impact the outcome of clinical trials for novel asthma therapies. Moreover, we are looking for partnerships to move LungBeat beyond asthma into other respiratory domains.
LungBeat®, already a clinically validated working product aims to expand its capabilities across various domains:
